Wockhardt Ltd (WOCKPHARMA)

📊 Quarterly Results (₹ Cr)

The company’s financial trajectory shows a decisive inflection point: revenue has grown from ₹782 crores (Sep 2025) to ₹965 crores (Mar 2026) and stabilized at ₹929 crores (Jun 2026), while profitability has improved sharply — NP margin rose from -14.6% in Q1 FY26 to 11.5% in Q1 FY27, and EBITDA margins expanded to 20.2%. Despite flat operating profit in the latest quarter (₹137 crores vs ₹172 crores in Mar 2026), net profit remained strong at ₹107 crores due to cost and margin optimization. The consistent revenue growth and margin recovery align directly with management’s stated focus on high-margin biotech and emerging markets.

🔮 Management Outlook & What's Next

Management has explicitly signaled future growth through the upcoming launch of insulin analogs over the next few years, positioning them as a key driver of international biotech revenue. The board has also reaffirmed its strategic focus on pharmaceuticals and capital expansion, with the ₹3,000 Crore fundraising seen as essential to fund R&D, global operations, and working capital needs. No formal long-term financial targets were provided, but the capital plans and product pipeline suggest a multi-year investment phase.

Extracted from official company announcements. Not StockFin.ai's opinion.

🏦 Balance Sheet (₹ Cr)

The balance sheet reflects a deliberate shift toward capital intensity: total assets grew to ₹8,615 crores by March 2026, driven by rising borrowings (₹2,125 crores) and stable equity of ₹81 crores plus reserves of ₹4,859 crores. While leverage (D/E of 0.43) remains moderate, the increase in borrowings signals active investment in growth initiatives, likely tied to the approved capital raise. The company is not deleveraging but using debt to fund expansion, consistent with its AGM-approved strategy.

💰 Cash Flow Statement (₹ Cr)

👥 Shareholding Pattern

Institutional interest is rising: FII holding increased from 6.99% (Q3FY26) to 7.22% (Q1FY27), and DII from 10.55% to 9.23%, despite promoter holding remaining flat at 49.08%. The number of shareholders has also grown from 1,37,946 (Q2FY26) to 1,66,518 (Q1FY27), indicating broader retail and institutional participation. This accumulation trend suggests improving confidence, particularly as the company demonstrates profitability recovery.

⚖️ Peer Comparison — Pharmaceuticals

🔗 Peer Stock Analyses

⚠️ Risk Factors

1) High valuation (P/E of 74.7) reflects elevated expectations, making the stock sensitive to execution delays in insulin launches or margin compression. 2) PAT margin improvement was partly driven by one-time gains and cost control; sustainability depends on competitive pricing and input cost management. 3) Related party transactions with Wockhardt Bio AG and others, while approved, carry governance scrutiny given the group structure. 4) Negative diluted EPS in consolidated results raises concerns about minority shareholdings’ impact on per-share metrics.

📋 Recent Filings

• Announcement2026-09-25Wockhardt Ltd announced the closure of its trading window effective October 1, 2026, following regulatory requirements tied to upcoming unaudited fina…
• 🟡 Board Meeting2026-08-10Wockhardt Limited disclosed its Monitoring Agency Report for the QIP issue, confirming no deviation in utilization of proceeds for the quarter ended J…
• 🟡 Board Meeting2026-08-10Wockhardt Limited held its 27th AGM on 10 August 2026, approving audited financial statements, appointing directors, sanctioning up to ₹1,000 Crore in…
• 🟡 Board Meeting2026-08-10Wockhardt Limited announced the outcome of its board meeting held on August 10, 2026, where it approved un-audited standalone and consolidated financi…
• 🔴 Financial Results2026-08-10Wockhardt reported a 26% YoY revenue increase to Rs.929 crores for Q1 FY27, driven by strong growth in emerging markets and biotech segments, while PA…
• 🟡 Board Meeting2026-08-05Wockhardt Limited announced an addendum to its notice for the 27th Annual General Meeting, revising the meeting time from 3:30 p.m. to 10:30 a.m. IST …
• share transfer2026-07-10Wockhardt Limited received a SEBI-mandated share transfer agent certificate for the quarter ended June 30, 2026, confirming dematerialized securities …
• 🟡 concall transcript2026-06-30Wockhardt's investor call on June 4, 2026, highlighted the US FDA approval of Zaynich, its first India-developed antibiotic, and strategic plans for U…
• Financial Results2026-06-25Wockhardt Limited announced that its trading window for equity shares will close on 1 July 2026 and remain shut for 48 hours following the release of …
• Announcement2026-06-11Wockhardt announced its US launch strategy for Zaynich, a novel antibiotic targeting carbapenem-resistant infections with 96.8% cure rates, backed by …

🧠 Analyst's Read

Wockhardt is executing a credible turnaround with strong top-line growth and margin recovery, underpinned by international biotech momentum and strategic capital access. Investors should monitor the pace of insulin analog launches, utilization of the ₹3,000 Crore capital, and whether margin expansion holds amid pricing pressures — key near-term catalysts that will determine the sustainability of this recovery.

Based on filing content and financial data. Not a recommendation.